share_log

Chardan Capital Maintains Sell on Mesoblast, Lowers Price Target to $2

Benzinga ·  May 30, 2023 07:32

Chardan Capital analyst Keay Nakae maintains Mesoblast (NASDAQ:MESO) with a Sell and lowers the price target from $2.5 to $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment